Pharmacogenetics and oral antithrombotic drugs
作者： William L Baker , Samuel G Johnson
DOI: 10.1016/J.COPH.2016.01.008
关键词: Pharmacogenetics 、 Therapeutic index 、 Pharmacology 、 Antithrombotic 、 VKORC1 、 Dosing 、 Fibrinolytic agent 、 Medicine 、 Adverse effect 、 Intensive care medicine 、 Warfarin 、 Drug discovery
摘要: Warfarin and other oral vitamin K antagonists (VKAs) have been the primary pharmacologic options with well-established efficacy data in high-risk patient populations. dose requirements to achieve therapeutic anticoagulation are highly variable. This variability response results increased risk for adverse events, including thromboembolism bleeding. Genetic variants CYP2C9 VKORC1 identified shown explain some of warfarin response. Prospective trials suggest that incorporation genotype faster time range than without; however, whether these improvements result improved clinical outcomes is unclear. The target-specific anticoagulants alternatives do not require laboratory monitoring. Some pharmacogenetic variation their may exist as well. Ongoing will provide a clearer picture genotype-based dosing improves may, therefore, subsequently be compared agents.
elsevier.com
sci-hub.se 参考文章(38)
TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329
Kaitlyn Shaw, Ursula Amstutz, Claudette Hildebrand, S. Rod Rassekh, Martin Hosking, Kathleen Neville, J. Steven Leeder, Michael R. Hayden, Colin J. Ross, Bruce C. Carleton, VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children Pediatric Blood & Cancer. ,vol. 61, pp. 1055- 1062 ,(2014) , 10.1002/PBC.24932
Jessica L Mega, Joseph R Walker, Christian T Ruff, Alexander G Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A Murphy, James Lee, Michele F Mercuri, Robert P Giugliano, Elliott M Antman, Eugene Braunwald, Marc S Sabatine, None, Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial The Lancet. ,vol. 385, pp. 2280- 2287 ,(2015) , 10.1016/S0140-6736(14)61994-2
Hersh Sagreiya, Caroline Berube, Alice Wen, Ramesh Ramakrishnan, Alain Mir, Amy Hamilton, Russ B. Altman, Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenetics and Genomics. ,vol. 20, pp. 407- 413 ,(2010) , 10.1097/FPC.0B013E328338BAC2
J Pink, M Pirmohamed, S Lane, D A Hughes, Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation Clinical Pharmacology & Therapeutics. ,vol. 95, pp. 199- 207 ,(2014) , 10.1038/CLPT.2013.190
Walter Ageno, Alexander S. Gallus, Ann Wittkowsky, Mark Crowther, Elaine M. Hylek, Gualtiero Palareti, Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. ,vol. 141, ,(2012) , 10.1378/CHEST.11-2292
Stephen D. Bendel, Robert Bona, William L. Baker, Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Advances in Therapy. ,vol. 28, pp. 460- 472 ,(2011) , 10.1007/S12325-011-0025-1
Joachim Stangier, Andreas Clemens, Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clinical and Applied Thrombosis-Hemostasis. ,vol. 15, ,(2009) , 10.1177/1076029609343004
P. A. LENZINI, G. R. GRICE, P. E. MILLIGAN, M. B. DOWD, S. SUBHERWAL, E. DEYCH, C. S. EBY, C. R. KING, R. M. PORCHE-SORBET, C. V. MURPHY, R. MARCHAND, E. A. MILLICAN, R. L. BARRACK, J. C. CLOHISY, K. KRONQUIST, S. K. GATCHEL, B. F. GAGE, Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients Journal of Thrombosis and Haemostasis. ,vol. 6, pp. 1655- 1662 ,(2008) , 10.1111/J.1538-7836.2008.03095.X
Virginia Pérez-Andreu, Vanessa Roldán, Ana Isabel Antón, Nuria García-Barberá, Javier Corral, Vicente Vicente, Rocio González-Conejero, Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy Blood. ,vol. 113, pp. 4977- 4979 ,(2009) , 10.1182/BLOOD-2008-09-176222